FAQ/Help |
Calendar |
Search |
Today's Posts |
![]() |
#1 | |||
|
||||
Senior Member
|
"For the 420 patients randomized, mean age was 63 and mean disease duration was 9 years. At 12 weeks, the mean daily off-time (the primary outcome) was significantly better than placebo in the tozadenant 120 mg twice-daily group (−1.1 hours), in the tozadenant 180 mg twice-daily group (−1.2 hours), and in these two dosing groups combined (−1.1 hours). The 60-mg group did not meet the primary outcome; nor did the 240-mg group, which had substantial dropouts resulting from adverse events. Dyskinesia, and to a lesser extent nausea and dizziness, were more common in those on active drug than in those on placebo.
Comment by Dr. M. Okin : Adenosine A2A receptors are abundant in the brain; many are colocated next to dopamine receptors. Istradefylline and preladenant, two other adenosine A2A receptor antagonists, recently had disappointing phase III results. The authors of the current study believe that they have addressed several issues with the methodology of previous trials. However, several important questions remain. Should we employ the adenosine approach early or later in PD? What symptoms are best addressed by adenosine antagonists? What is the adverse-event profile, particularly in elders with multiple comorbidities? Will patients prefer a change in doses and intervals of dopaminergic drugs, rather than adding another compound? How cost-effective will this approach be? If phase III results with tozadenant are positive, we will need to begin to answer these questions. - See more at: NEJM watch
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson Last edited by olsen; 08-17-2014 at 12:24 PM. |
|||
![]() |
![]() |
"Thanks for this!" says: | soccertese (08-18-2014) |
|
|
![]() |
||||
Thread | Forum | |||
Adenosine | Peripheral Neuropathy | |||
Shock treatments making a comeback! | Survivors of Suicide | |||
Why no trials yet of tnf-a and il-1 antagonists? | Parkinson's Disease |